7498 Results (Page 199 of 300)
Pharmaceuticals Markets Research Reports
Vietnam Dermatological Therapeutics Market Analysis
Vietnam Dermatological Therapeutics Market is at around $0.21 Bn in 2023 and is projected to reach $0.37 Bn in 2030, exhibiting a CAGR of 8.83% during the forecast period. Advances in technology, the prevalence of skin disorders, and increased awareness of skin health are driving the expansion of the market. The market is dominated by key players like Almirall SA, Pfizer Inc., GlaxoSmithKline Plc (GSK), AbbVie Inc., Amgen Inc., Novartis AG, Roche, Sanofi, Bayer, and Johnson & Johnson.
Indonesia Dermatological Therapeutics Market Analysis
Indonesia Dermatological Therapeutics Market is at around $0.25 Bn in 2023 and is projected to reach $0.44 Bn in 2030, exhibiting a CAGR of 8.6% during the forecast period. The market is expanding due to an increase in dermatological disorders, increased awareness about skin diseases, and technological advancements. The market is dominated by key players like PT Kalbe Farma Tbk (IDN), PT Kimia Farma Tbk (IDN), PT Sanbe Farma (IDN), Almirall SA, Pfizer Inc., AbbVie Inc., Amgen Inc., Novartis AG, Johnson & Johnson, and GlaxoSmithKline Plc.
China Dermatological Therapeutics Market Analysis
China Dermatological Therapeutics Market is at around $3.34 Bn in 2023 and is projected to reach $6.54 Bn in 2030, exhibiting a CAGR of 10.1% during the forecast period. The market is growing as a result of urbanization, increasing elderly population, and growing awareness. The market is dominated by key players like Fosun Pharma (CHN), Sinopharm (CHN), Jiangsu Hengrui Medicine (CHN), CSPC Pharmaceutical Group (CHN), Hualan Biological Engineering (CHN), Harbin Pharmaceutical Group (CHN), Yunna Baiyao Group (CHN), Sino Biopharmaceutical (CHN), Pfizer, Johnson & Johnson, Novartis AG, and GlaxoSmithKline PLC.
UK Dermatological Therapeutics Market Analysis
UK Dermatological Therapeutics Market is at around $1.04 Bn in 2023 and is projected to reach $1.63 Bn in 2030, exhibiting a CAGR of 6.6% during the forecast period. The market is driven by the rising prevalence of skin disorders, developments in dermatology research and technology, and patient awareness and education. The market is dominated by key players like LEO Pharma, Almirall SA, Pfizer Inc., AbbVie Inc., Amgen Inc., Novartis AG, Gladerma Laboratories, Johnson & Johnson, Eli Lilly and Company, and GlaxoSmithKline Plc.
Spain Dermatological Therapeutics Market Analysis
Spain Dermatological Therapeutics Market is at around $0.78 Bn in 2023 and is projected to reach $1.31 Bn in 2030, exhibiting a CAGR of 7.6% during the forecast period. The market is expanding due to factors such as trends in cosmetic dermatology, healthcare infrastructure and access to dermatological care, and advancements in dermatology technology. The market is dominated by key players like Skin Tech Pharma, Grupo Juste, Merck KGaA, Boehringer Ingelheim, Almirall SA, Pfizer Inc., AbbVie Inc., Amgen Inc., Novartis AG, and Gladerma Laboratories.
Germany Dermatological Therapeutics Market Analysis
Germany Dermatological Therapeutics Market is at around $1.47 Bn in 2023 and is projected to reach $2.34 Bn in 2030, exhibiting a CAGR of 6.8% during the forecast period. The market is being driven by an aging population, an increase in dermatological conditions, and advances in research and development. The market is dominated by key players like Beiersdorf, Stada Arzneimittel, Merck KGaA, Boehringer Ingelheim, Almirall SA, Pfizer Inc., AbbVie Inc., Amgen Inc., Novartis AG, and Gladerma Laboratories.
France Dermatological Therapeutics Market Analysis
France Dermatological Therapeutics Market is at around $1.12 Bn in 2022 and is projected to reach $1.86 Bn in 2030, exhibiting a CAGR of 7.6% during the forecast period. The market is propelling due to the rising incidence of dermatological conditions, increasing awareness about skin disorders, and growing demand for cosmetic dermatology. The market is dominated by key players like Pierre Fabre (France), Boiron (France), Lallemand Pharma (France), Almirall SA, Pfizer Inc., AbbVie Inc., Amgen Inc., Novartis AG, Gladerma Laboratories, and Bausch Health Companies Inc.
Mexico Dermatological Therapeutics Market Analysis
Mexico Dermatological Therapeutics Market is at around $0.62 Bn in 2022 and is projected to reach $1.11 Bn in 2030, exhibiting a CAGR of 8.85% during the forecast period. The market is rapidly expanding as a result of the increased prevalence of dermatological conditions, rising awareness about skin disorders, and technological advancements in the industry. The market is dominated by key players like Genomma Lab Internacional, Almirall SA, Pfizer Inc., AbbVie Inc., Amgen, Gladerma Laboratories, Bausch Health Companies Inc., Novartis AG, Eli Lily and Company, and GlaxoSmithKline PLC.
Brazil Dermatological Therapeutics Market Analysis
Brazil Dermatological Therapeutics Market is at around $1.03 Bn in 2023 and is projected to reach $1.96 Bn in 2030, exhibiting a CAGR of 9.6% during the forecast period. The market is growing due to factors such as rising dermatological disorders, e-commerce and digital marketing, and technological advancements. The market is dominated by key players like Hypermarcas, Ache Laboratorios Farmaceuticos S.A., EMS: Industria Farmaceutica S.A., Almirall SA, Pfizer Inc., AbbVie Inc., Amgen, Gladerma SA, Johnson & Johnson, Novartis AG, Eli Lily and Company, Sun Pharmaceuticals Ltd., and GlaxoSmithKline PLC.
UAE Dermatological Therapeutics Market Analysis
UAE Dermatological Therapeutics Market is at around $0.21 Bn in 2023 and is projected to reach $0.39 Bn in 2030, exhibiting a CAGR of 9.6% during the forecast period. The market is being driven by advancements in dermatological research, medical tourism, and growing awareness of skin health. The market is dominated by key players like Neopharma, Julphur, Almirall SA, Pfizer Inc., AbbVie Inc., Amgen, Gladerma SA, Johnson & Johnson, Novartis AG, Eli Lily and Company, Sun Pharmaceuticals Ltd., and GlaxoSmithKline PLC.
Saudi Arabia Dermatological Therapeutics Market Analysis
Saudi Arabia Dermatological Therapeutics Market is at around $0.71 Bn in 2023 and is projected to reach $1.38 Bn in 2030, exhibiting a CAGR of 10.1% during the forecast period. The market is expanding due to trends in cosmetic dermatology, supportive regulatory frameworks, and growing distribution networks. The market is dominated by key players like Jamjoom Pharma Company, Tabuk Pharmaceutical Manufacturing Company, Almirall SA, Pfizer Inc., AbbVie Inc., Amgen, Gladerma SA, Johnson & Johnson, Novartis AG, Eli Lily and Company, Sun Pharmaceuticals Ltd., and GlaxoSmithKline PLC.
US Dermatological Therapeutics Market Analysis
US Dermatological Therapeutics Market is at around $16.88 Bn in 2023 and is projected to reach $26.40 Bn in 2030, exhibiting a CAGR of 6.6% during the forecast period. The development of innovative therapies, the growing trend of cosmetic dermatology, and the increasing prevalence of skin conditions are driving the growth of the market. The market is dominated by key players like Almirall SA, Pfizer Inc., AbbVie Inc., Amgen, Gladerma SA, Johnson & Johnson, Novartis AG, Eli Lily and Company, Sun Pharmaceuticals Ltd., and GlaxoSmithKline PLC.
US Vitamin and Minerals Market Analysis
This report presents a strategic analysis of the US Vitamin and Minerals Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the US Vitamin and Minerals Market, offering unmatched value, accuracy, and expert insights.
US Lung Cancer Drugs Market Analysis
US Lung Cancer Drug Market is projected to grow from $4.015 Bn in 2022 to $6.546 Bn by 2030, registering a CAGR of 6.3% during the forecast period of 2022-30. The incidence of lung cancer is increasing globally, which is leading to a growing demand for lung cancer drugs in the US market. Key players operating in the market include Pfizer, Bristol-Myers Squibb, Merck, AstraZeneca, and Roche.
US Diabetes Therapeutics Market Analysis
US's diabetes therapeutics market is projected to grow from $60.4 Bn in 2022 to $109.4 Bn by 2030, registering a CAGR of 7.7% during the forecast period of 2022-30. Diabetes is a chronic disease that affects millions of people in the US. According to the Centers for Disease Control and Prevention (CDC), over 34 million people in the US have diabetes, and the prevalence of the disease is increasing. This has led to an increase in demand for diabetes therapeutics. Some of the key players in the US diabetes therapeutics market include Novo Nordisk, Sanofi, Eli Lilly and Company, AstraZeneca, and Merck & Co. These companies are focusing on research and development activities to introduce new and innovative drugs and therapies to address the unmet needs of diabetic patients.
Indonesia Cardiovascular Drugs Market Analysis
Indonesia Cardiovascular Drug Market is at around $0.83 Bn in 2022 and is projected to reach $1.12 Bn in 2030, exhibiting a CAGR of 3.8% during the forecast period. The main elements propelling this industry's growth include the incidence of cardiovascular diseases, changing lifestyles, and the aging population. The market is dominated by key players like Kalbe Pharma, Kimia Pharma, Bristol-Myers Squibb Company, Pfizer Inc., Bayer AG, Janssen Pharmaceuticals, Inc., AstraZeneca, Sanofi, Novartis AG, and Gilead Sciences, Inc.
Brazil Anemia Therapeutics Market Analysis
The Brazil Anemia Therapeutics Market is anticipated to experience growth from $370 Mn in 2022 to $799 Mn by 2030, with a CAGR of 10.10% during the forecast period of 2022–2030. Factors such as the demography and disease burden in Brazil, increasing adaptation of healthcare innovations and advancements, and lenient and fast regulatory policies, drive market growth. The Brazil Anemia Therapeutics Market encompasses various players across different segments, including Amgen, Roche, Novartis, Eli Lilly, Sanofi, Cristalia Pharma, Ache Laboratories, EMS Pharma, Eurofarma, BioLab Pharma, etc, among various others
Canada Cardiovascular Drugs Market Analysis
Canada Cardiovascular Drug Market is at around $11.1 Bn in 2022 and is projected to reach $14.91 Bn in 2030, exhibiting a CAGR of 3.8% during the forecast period. One major factor propelling the market’s expansion is personalized medicine. It utilizes a patient's genetic and molecular profile to customize treatment. The market is dominated by key players like Bristol-Myers Squibb Canada Co, Pfizer Canada, Bayer AG, Janssen Pharmaceuticals, Inc., AstraZeneca Canada Inc., Sanofi-Aventis Canada Inc., Novartis Pharmaceuticals Canada, Merck & Co., Inc., Gilead Sciences Canada, Inc., and F. Hoffman-La Roche Ltd.
Vietnam Alopecia (Hair Loss) Therapeutics Market Analysis
The Vietnam Alopecia (Hair Loss) Therapeutics Market was valued at US $41 Mn in 2022, and is predicted to grow at (CAGR) of 7.73% from 2023 to 2030, to US $74 Mn by 2030. The main drivers advancing this industry are primarily the significant rise in the prevalence of alopecia (hair loss), demographic shifts, lifestyle modifications, and others. The industry is primarily dominated by players such as Sun Pharmaceuticals, Johnson & Johnson, Cirrus, Cipla, Lexington, and Merck, among others
US Alopecia (Hair Loss) Therapeutics Market Analysis
The US Alopecia (Hair Loss) Therapeutics Market was valued at US $3.444 Bn in 2022, and is predicted to grow at (CAGR) of 5.50% from 2023 to 2030, to US $5.285 Bn by 2030. The key drivers of this industry include the upward trend in the prevalence of alopecia (hair loss), technological advancements, and others. The industry is primarily dominated by players such as Eli Lilly, Johnson & Johnson, Cipla, Mylan, Theradome, and Pfizer, among others.
UK Alopecia (Hair Loss) Therapeutics Market Analysis
The UK Alopecia (Hair Loss) Therapeutics Market was valued at US $213 Mn in 2022, and is predicted to grow at (CAGR) of 5.5% from 2023 to 2030, to US $327 Mn by 2030. The key drivers of this industry include the surge in the prevalence of Alopecia (hair loss), increased disposable income, technological advancements, and others. The industry is primarily dominated by players such as Johnson & Johnson, Eli Lilly, Merck, Cipla, Sun Pharmaceuticals, Allergan, and Pfizer, among others.
UAE Alopecia (Hair Loss) Therapeutics Market Analysis
The UAE Alopecia (Hair Loss) Therapeutics Market was valued at US $41 Mn in 2022, and is predicted to grow at (CAGR) of 8.5% from 2023 to 2030, to US $79 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of alopecia (hair loss), demographic changes, and others. The industry is primarily dominated by players such as Johnson & Johnson, Eli Lilly, Aclaris, Cipla, Follicum, Theradome, and Pfizer, among others
Spain Alopecia (Hair Loss) Therapeutics Market Analysis
The Spain Alopecia (Hair Loss) Therapeutics Market was valued at US $158 Mn in 2022, and is predicted to grow at (CAGR) of 6.5% from 2023 to 2030, to US $262 Mn by 2030. The key drivers of this industry include the surge in the prevalence of Alopecia (hair loss), increased disposable income, technological advancements, and others. The industry is primarily dominated by players such as Johnson & Johnson, Eli Lilly, Merck, Cipla, Sun Pharmaceuticals, Allergan, and Pfizer, among others.
South Africa Alopecia (Hair Loss) Therapeutics Market Analysis
The South Africa Alopecia (Hair Loss) Therapeutics Market was valued at US $53 Mn in 2022, and is predicted to grow at (CAGR) of 8.73% from 2023 to 2030, to US $104 Mn by 2030. The main drivers advancing this industry are primarily the significant rise in the prevalence of alopecia (hair loss), emerging treatment alternatives in response to demand, and others. The industry is primarily dominated by players such as Pfizer, Merck, Eli Lilly, Johnson & Johnson, Bayer, and Lutronic, among others.
Singapore Alopecia (Hair Loss) Therapeutics Market Analysis
The Singapore Alopecia (Hair Loss) Therapeutics Market was valued at US $10 Mn in 2022, and is predicted to grow at (CAGR) of 8.1% from 2023 to 2030, to US $18 Mn by 2030. The primary factors propelling this industry forward include the notable increase in the prevalence of alopecia (hair loss), demand for effective treatments, and others. The industry is primarily dominated by players such as Sun Pharmaceuticals, Johnson & Johnson, Capillus, Follica Inc., Lexington, and Merck, among others.
